Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

The Only Negotiation that Matters?

This article was originally published in RPM Report

Executive Summary

Economists looking at drug prices under Medicare agree on one thing: without control over formularies HHS won't have the power to drive discounts. One told Congress that instead of giving HHS more power, you should give plans full discretion to set formularies, even in the so-called protected classes. But don't count on that happening any time soon.
Advertisement

Related Content

Putting the Bully in the Bully Pulpit: The Democrats' Plan to Cut Drug Prices
Putting the Bully in the Bully Pulpit: The Democrats' Plan to Cut Drug Prices
Competing Priorities: Alzheimer's Drugs and the Delicate Balance that Defines Part D
Medicare's Privileged Drug Classes: Price Protections Through 2007
CATIE: Learning to Live With large Comparative Trials

Topics

Advertisement
UsernamePublicRestriction

Register

PS080225

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel